SCHEMBL7010272

SCHEMBL7010272

c1ncc(CC2=NCCN2)cn1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 6/20 0.59
ADRA2A P08913 2/20 0.59
ADRA2B P18089 2/20 0.59
ADRA2C P18825 2/20 0.59
ADRA1D P25100 2/20 0.59
ADRA1A P35348 2/20 0.59
ADRA1B P35368 2/20 0.59
CYP2D6 P10635 2/20 0.59
LMNA P02545 1/20 0.59
CYP1A2 P05177 1/20 0.59
TSHR P16473 1/20 0.59
HTR1D P28221 8/20 0.56
HTR1B P28222 6/20 0.51
NFKB1 P19838 1/20 0.50
RAD52 P43351 1/20 0.47
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
NISCH Q9Y2I1 1/20 0.44
PTGIR P43119 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7009403 0.89 TAAR1 (0.47) TAAR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL7004570 0.80 TAAR1 (0.69) TAAR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL10846015 0.78 TAAR1 (0.72) TAAR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL7011502 0.78 HTR1D (0.61) TAAR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL10378155 0.76 TAAR1 (0.61) TAAR1ADRA2AADRA2BADRA2CADRA1D
Tolazoline SCHEMBL34961 0.74 TAAR1 (1.00) TAAR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL4037274 0.73 HTR1D (0.71) TAAR1ADRA2AADRA2BADRA2CADRA1D
Tolazoline SCHEMBL5053858 0.73 TAAR1 (1.00) TAAR1ADRA2AADRA2BADRA2CADRA1D
Tolazoline SCHEMBL28254903 0.73 TAAR1 (0.96) TAAR1ADRA2AADRA2BADRA2CADRA1D
Tolazoline SCHEMBL34869 0.73 TAAR1 (1.00) TAAR1ADRA2AADRA2BADRA2CADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030100769-A1 Cyclic amidine compounds DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-05-29 US claimed
EP-1280793-A2 CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS SUNTORY LIMITED (JP) 2003-02-05 EP claimed
WO-2001081334-A2 CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS SUNTORY LIMITED (JP) 2001-11-01 WO claimed
US-20030100769-A1 Cyclic amidine compounds DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-05-29 US disclosed
EP-1280793-A2 CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS SUNTORY LIMITED (JP) 2003-02-05 EP disclosed
WO-2001081334-A2 CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS SUNTORY LIMITED (JP) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100769-A1 Cyclic amidine compounds CHRM1, CHRM5, CCKAR TAAR1 65/4885ADRA2A 262/4885ADRA2B 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.